ClinicalTrials.gg
CompletedNCT06220331Updated Jan 23, 2024

Data Collection After Intensity IOL Implantations

An observational study in Cataract, sponsored by Hanita Lenses. Completed at 1 site in Argentina. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-01-23.

Sponsored by Hanita Lenses · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
31
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Cataract by Hanita Lenses — 2 open to participants now, 2 under way, none of them phase 3. Cataract · Hanita Lenses.

Started
2023
with 3 others
Observational
2 of 10
none open now
Registered
10th of 10
by date

Among the 10 studies in Cataract by Hanita Lenses, this one is one of 4 that started in 2023, is one of 2 observational ones, and was the 10th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

2 of the 10 studies in Cataract by Hanita Lenses are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Cataract by Hanita Lenses, or all of them as a file.
02

Study summary

Hanita Lenses new Intensity IOL and Intensity Toric were been designed to have very high efficiency of light leading to a high MTF, wide focal ranges of far, intermediate and near vision and minimal loss of light energy. The main purpose of this study is to collect existing post-operative data based on standard of care follow up visits at the clinic.

Read the detailed description

Different multifocal intraocular lens (MIOL) designs have been used for more than 25 years1. Unlike conventional mono focal intraocular lenses (IOLs), which bend light to a single focus point on the retina, MIOLs are designed to help patients to see at varying distances using different points of focus2. MIOLs used in clinical practice were either refractive initially, or later diffractive in their optical design. Refractive MIOLs incorporate a lens optic with different optical powers in different parts of the lens, while diffractive MIOLs use diffractive steps on the lens to distribute light rays into two or more principal foci. Irrespective of the design type, however, all MIOLs involve some form of optical compromise and a process of neuroadaptation for the patient.

Intensity SL intraocular lenses (IOLs) represent the latest in premium lens technology. Intensity SL lenses provide clear vision at all distances - from near to far - thus offering the best chance of true spectacle independence.

Despite the promising results obtained with the latest generation of MIOLs, many surgeons remain reluctant to implant these lenses. Visual symptoms such as glare and haloes, reduced contrast sensitivity and night vision problems are all known complications of multifocal implants and have served to hamper wider acceptance of these IOLs4.

Hanita Lenses new Intensity IOL and Intensity Toric were been designed to have very high efficiency of light leading to a high MTF, wide focal ranges of far, intermediate and near vision and minimal loss of light energy. The main purpose of this study is to collect existing post-operative data based on standard of care follow up visits at the clinic.

03

Conditions studied

  • Cataract

Browse trials for

Keywords

  • Intra Ocular Lens
  • Intensity SL
  • Hanita Lenses
  • Cataract
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Men and women that had implantation with Hanita Intensity IOL or Intensity Toric Lenses in the clinic participating in the study. The patients that suffered from cataract and operated with implantation of Hanita Intensity MIOL or Intensity Toric MIOL in the clinic participating in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient over the age of 18
  • Patient who underwent bilateral implantations with Hanita Lenses Intensity IOL

Exclusion criteria

Exclusion Criteria:

  • Patients who don't have any follow up visits after implantation
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
31 participants (actual)
Patient registry
No

Groups and cohorts

  • Elder patients diagnosed with cataract

    Patients that diagnosed with cataract and had implantation with Hanita Intensity IOL or Intensity Toric Lenses in the clinic participating in the study.

    Device: Intra Ocular Lens

Interventions

  • DeviceIntra Ocular Lens

    Intensity SL Intra Ocular Lens

06

What researchers measure

Primary outcomes

  1. The aim of this study is to evaluate performance of Hanita Lenses Intensity SL IOL.

    Performance of the IOL will be evaluated by assessing the defocus Curve and visual acuity for far, intermediate and near distance after Intensity SL IOL implantation.

    Time frame: 1-3 months

Secondary outcomes

  1. The second aim of this study is to evaluate the visual phenomena post-operation.

    Visual phenomena will be evaluated by asking the patients about halos ang glares

    Time frame: 1-3 months

07

Study locations

1 site
  • Consejo Argentino de Oftalmología
    Buenos Aires, Argentina
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Sep 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2024
First posted
Jan 23, 2024
StartActual
Jul 13, 2023
Primary completionActual
Sep 1, 2023
CompletionActual
Sep 30, 2023
Last update
Jan 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06220331
Lead sponsor
Hanita Lenses
Responsible party
Sponsor
First posted
Jan 23, 2024
Start date
Jul 13, 2023
Primary completion
Sep 1, 2023
Completion
Sep 30, 2023
Last update
Jan 23, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion